QUÉBEC CITY, QUÉBEC--(Marketwired - Nov. 7, 2016) -
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
M. André Boulet, President, CEO and Chairman of Devonian Health Group Inc a pharmaceutical company based in Québec Canada and Benoit Chotard, President of Orletto Capital inc. ("Orletto" or the "Corporation") (TSX VENTURE:OLE.P) who will propose to their shareholders to amalgamate at shareholder meetings to be held respectively on November 8, 2016 and November 25, 2016 to form a new entity called Groupe Santé Devonian Health Group Inc/Groupe Santé Devonian inc ("Devonian") are pleased to announce the appointment of Dr. Jean-Claude Tardif, CM, MD, FRCPC, FCCS, FACC, FAHA, FESC, FCAHS as Chairman of the Scientific Advisory Board ("SAB") of Devonian, which will serve as a strategic resource to Devonian as it advances its clinical program.
"We are thrilled to have Dr. Tardif join Devonian as the Chairman of the Scientific Advisory Board. Dr Tardif has tremendous expertise in drug discovery and development, which we believe will be valuable in shaping the strategic direction of Devonian. We look forward to gaining counsel from Dr. Tardif on the assessment of various scientific and clinical opportunities as well as ongoing development of our clinical program. We plan to further expand our SAB to include renowned key opinion leaders in inflammatory / auto-immune diseases who will play a key role in Devonian's scientific and clinical development initiatives," said Dr. André P. Boulet, Ph.D., President, CEO and Chairman of Devonian.
"I am very pleased to chair the Scientific Advisory Board and work with the Devonian team to advance Devonian's current and future therapeutic programs. Devonian is taking a unique and exciting approach that may bring new therapies to market in a more efficient manner, targeting areas of high unmet medical need. I am excited to support the team as they work to bring these innovative therapies to the market," stated Dr. Jean-Claude Tardif, Chairman of Devonian's Scientific Advisory Board.
About Dr Jean-Claude Tardif, MD
Jean-Claude Tardif is the Director of the Research Centre at the Montreal Heart Institute and Professor of Medicine at the University of Montreal. Dr. Tardif graduated from the University of Montreal with his medical degree in 1987 and completed his training in cardiology and research in Montreal and Boston in 1994. Dr. Tardif holds the Canada Research Chair in translational and personalized medicine and the University of Montreal endowed research chair in atherosclerosis. He is the Scientific Director of the Montreal Health Innovations Coordinating Centre (MHICC) and Chairman of the steering committees of the CIHR-funded Canadian Atherosclerosis Imaging Network (CAIN) and Medical Imaging Trials Network of Canada (MITNEC).
Dr. Tardif has authored and co-authored more than 800 articles and abstracts in peer-reviewed publications, including the New England Journal of Medicine, the Journal of the American Medical Association, The Lancet, Circulation, the Journal of the American College of Cardiology, the European Heart Journal, Nature Genetics, Genes and Development, the British Journal of Pharmacology, and Cardiovascular Research. In addition, he has written more than 30 book chapters (including in Braunwald's Textbook of Heart Disease) and has edited several books. He has given approximately 400 invited lectures around the world.
His research covers the molecular and genomic aspects of atherosclerosis and related diseases and also involves pre-clinical models, mechanistic and observational clinical studies as well as large international randomized clinical trials. Dr. Tardif is or has been the international principal investigator or part of the study leadership of several large clinical trials in the field of atherosclerosis and other cardiovascular diseases.
Dr. Tardif and his team have created the Beaulieu-Saucier Pharmacogenomics Center at the Montreal Heart Institute and he has created the Center of Excellence in Personalized Medicine (CEPMed), the latter funded by the Network of Centers of Excellence (NCE) of Canada and which is also supported by multiple pharmaceutical and biotechnological companies. He is one of the founding fathers of the International Partnership for Critical Markers of Disease (CMOD) organization, which focuses on the development and better use of biomarkers (www.cmod.org).
Dr. Tardif has won multiple awards during his career, including the Research Achievement Award of the Canadian Cardiovascular Society, the Genesis Award of BIOQuebec (for his outstanding contributions to life sciences) and the Armand-Frappier Award of the Government of Quebec (the highest scientific distinction in Quebec). He was also named scientific personality of the year by La Presse newspaper. Because of his accomplishments, Dr. Tardif was named Fellow of the Canadian Academy of Health Sciences (FCAHS) and was recently inducted into the Order of Canada.
Orletto is a Capital Pool Company created pursuant to the Policy 2.4 and, to date, has not conducted material operations of any kind, other than to identify and evaluate businesses and assets with a view to completing a Qualifying Transaction. On September 9, 2014, Orletto completed its initial public offering, and the Orletto common shares commenced trading on the Exchange. Since incorporation, Orletto has incurred costs in carrying out its initial public offering, in seeking, evaluating and negotiating potential Qualifying Transactions, and in meeting the disclosure obligations imposed upon it as a reporting issuer.
Devonian is a late stage botanical pharmaceutical company with novel therapeutic approaches targeting unmet medical needs. Devonian's core strategy is to develop prescription botanical drugs. This strategy is supported by US-FDA set of regulatory guidelines favouring a more efficient drug development pathway versus traditional prescription medicines. Devonian is based on a broad-based platform originating from over ten years of research. This platform provides a unique process of extraction, purification, stabilization and conditioning of a molecular complex responsible for the photosynthetic process in plants and algae: The Supra Molecular Complex Extraction and Stabilisation Technology (SUPREX). The "Thykamine(TM)" is the first product issued from this platform. The potent anti-inflammatory and anti-oxidative activities of "Thykamine(TM)" have been demonstrated in several pre-clinical experiments as well as in a Phase 2a "proof of concept" clinical study in patients with mild-to-moderate distal ulcerative colitis. The product is now moving into large phase 2 clinical trials in two therapeutic areas: Ulcerative Colitis and Atopic Dermatitis. While the development of prescription botanical drugs is its core business, Devonian is also involved in the development of high value derma-cosmeceutical products as part of a secondary strategy to generate short-term revenues and optimize manufacturing efficiency.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
The statements contained herein that are not historical facts are forward-looking statements. These statements address future events and conditions and so involve inherent risks and uncertainties. Actual results could differ from those currently projected. The Corporation does not assume the obligation to update any forward-looking statement.